CoChat

Evaluation of treatment response in extrapulmonary tuberculosis in a low-resource setting

Open access
Jørstad, Melissa Davidsen, Dyrhol-Riise, Anne Ma, Aßmus, Jörg, Marijani, Msafiri, Sviland, Lisbet, Mustafa, Tehmina · 2019 · BMC Infectious Diseases

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Diagnosing extrapulmonary tuberculosis (EPTB) is challenging and many patients are initiated on empirical anti-TB treatment without a laboratory confirmed diagnosis. Monitoring treatment response is thus important to ensure correct diagnosis and proper disease management. The definition of satisfactory response to treatment in EPTB remains unclear. The objectives of this study were to describe the clinical presentation of EPTB and the effect of treatment on clinical parameters. Further, to assess if simple clinical parameters, without laboratory data, could evaluate treatment response. METHODS: Prospective cohort study of presumptive EPTB patients at Mnazi Mmoja Hospital, Zanzibar. By using a composite reference standard, patients were categorized as TB or non-TB cases. The TB patients were followed during anti-TB treatment. RESULTS: There were 64 TB and 62 non-TB cases. The frequency of symptoms at baseline were comparable in TB and non-TB patients, with lymphadenitis and pleuritis as the most common manifestations. Among TB cases, there was a trend towards regression of lymphadenopathy after 2 months, and at treatment completion 24/28 (86%) cases showed full regression. Weight gain ≥5% was reported in 36/49 (73%) of the TB patients at 2 months and in 38/46 (83%) at treatment completion. After 2 months of treatment, a combination of clinical parameters; improvement of symptoms (50/50), ≥5% weight gain (36/49) and regression of physical signs (45/49) correlated with the treatment response. CONCLUSIONS: An algorithm including only simple clinical parameters could be used as an easy tool to assess treatment responses in low-resource settings. However, this needs to be tested on a larger sample size.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12879-019-4034-z

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Time series plot illustrating the regression of lymphadenopathy during anti-TB treatment. The lymph node size (long axis of largest swelling) is presented at baseline, after 2 months of treatment and at treatment completion according to TB category (confirmed, probable and possible TB cases) and age. Each patient is represented by an individual line. At baseline, all, except one case, had lymph node enlargement > 2 cm. At 2 months, there was a trend in regression of lymph node swellings, and at treatment completion, 4 (14%) cases had residual lymphadenopathy. The patients with residual lymphadenopathy were all confirmed TB cases. Abbreviation: TB, tuberculosis
Fig. 1 Time series plot illustrating the regression of lymphadenopathy during anti-TB treatment. The lymph node size (long axis of largest swelling) is presented at baseline, after 2 months of treatment and at treatment completion according to TB category (confirmed, probable and possible TB cases) and age. Each patient is represented by an individual line. At baseline, all, except one case, had lymph node enlargement > 2 cm. At 2 months, there was a trend in regression of lymph node swellings, and at treatment completion, 4 (14%) cases had residual lymphadenopathy. The patients with residual lymphadenopathy were all confirmed TB cases. Abbreviation: TB, tuberculosisCC BY · PubMed Central
Fig. 2 Boxplots showing the weight change at 2 months of anti-TB treatment and at treatment completion. Left boxplot: weight change in kg between treatment onset and 2 months of treatment and between treatment onset and end of treatment according to site of TB infection, HIV status and age. Right boxplot: weight change as percentage change in weight between treatment onset and 2 months of treatment and between treatment onset and end of treatment according to site of TB infection, HIV status and age. Abbreviations: TB, tuberculosis; HIV, human immunodeficiency virus
Fig. 2 Boxplots showing the weight change at 2 months of anti-TB treatment and at treatment completion. Left boxplot: weight change in kg between treatment onset and 2 months of treatment and between treatment onset and end of treatment according to site of TB infection, HIV status and age. Right boxplot: weight change as percentage change in weight between treatment onset and 2 months of treatment and between treatment onset and end of treatment according to site of TB infection, HIV status and age. Abbreviations: TB, tuberculosis; HIV, human immunodeficiency virusCC BY · PubMed Central
Fig. 3 Clinical parameters at 2 months of treatment for assessment of treatment outcome. Left figure: Shows the number of patients having each clinical parameter. 1 – improvement of reported symptoms such as coughing, fever, appetite, fatigue and general condition. 2a – any weight gain compared to baseline; 2b - ≥5% weight gain compared to baseline; 3 - regression of objective findings. Right figure: Shows the number of patients having the sum of clinical parameters. Abbreviation: TB, tuberculosis
Fig. 3 Clinical parameters at 2 months of treatment for assessment of treatment outcome. Left figure: Shows the number of patients having each clinical parameter. 1 – improvement of reported symptoms such as coughing, fever, appetite, fatigue and general condition. 2a – any weight gain compared to baseline; 2b - ≥5% weight gain compared to baseline; 3 - regression of objective findings. Right figure: Shows the number of patients having the sum of clinical parameters. Abbreviation: TB, tuberculosisCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/201613. Geneva: WHO; 2016.

Cited by

See all 33

Metadata

Authors
Jørstad, M. D., Dyrhol-Riise, A. M., Aßmus, J., Marijani, M., Sviland, L., & Mustafa, T.
Affiliations
  • Haukeland University Hospital (NO)
  • Government of Tanzania (TZ)
Corresponding author
Jørstad, Melissa Davidsen
Venue
BMC Infectious Diseases
Published
2019-05-16
Volume
19
Issue
1
Pages
426-426
ISSN
1471-2334 (ISSN-L)
OpenAlex
W2945413152
Cited by
32
References
23
Citations by year
2026: 3 · 2025: 4 · 2024: 7 · 2023: 2 · 2022: 8 · 2021: 5 · 2020: 3
FWCI
3.07
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Infectious Diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Norges Forskningsråd (project number 234457)
  • Haukeland Universitetssjukehus (Not applicable)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords
extrapulmonary tuberculosis, treatment response assessment, clinical features, weight gain, lymphadenitis, pleurisy, resource-limited settings, diagnostic algorithm, Zanzibar
MeSH terms
Lymphadenopathy, Adolescent, Adult, Antitubercular Agents, Ascitic Fluid, Child, Female, Hospitals, Humans, Male, Middle Aged, Pleural Effusion, Prospective Studies, Tanzania, Tuberculosis, Cohort Studies, Weight Gain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of treatment response in extrapulmonary tuberculosis in a low-resource setting. https://app.cochat.ai/papers/10.1186/s12879-019-4034-z
The paper
Jørstad, M. D., Dyrhol-Riise, A. M., Aßmus, J., Marijani, M., Sviland, L., & Mustafa, T. (2019). Evaluation of treatment response in extrapulmonary tuberculosis in a low-resource setting. BMC Infectious Diseases. https://doi.org/10.1186/s12879-019-4034-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.